3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
4
Lymphoid
3
Dermatologic
3
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Interventions
venetoclax
33
fludarabine
32
Cyclophosphamide
31
Azacitidine
29
Specimen Handling
27
Biopsy
19
Cytarabine
18
fludarabine phosphate
15
Whole-Body Irradiation
15
Stem Cell Transplantation
15
Decitabine
15
ruxolitinib
14
Tacrolimus
14
Melphalan
14
Busulfan
14
Mycophenolic Acid
13
asciminib
10
Injections
10
decitabine and cedazuridine drug combination
8
Thiotepa
8
Methotrexate
8
Hematopoietic Stem Cell Transplantation
8
X-Rays
7
Granulocyte Colony-Stimulating Factor
7
Magnetic Resonance Spectroscopy
6
Idarubicin
6
Filgrastim
6
Cyclosporine
6
Blood Specimen Collection
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fecal Microbiota Transplantation
×
Myeloid
×
Clear all
NCT04935684
2023-03-01
TMF-Allo
University Hospital, Clermont-Ferrand
Phase 2
Recruiting
150 enrolled